Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 24;38(1):21–30. doi: 10.1038/s41375-023-02083-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — The figure shows treatment outcomes for 64 patients treated in the IR and HR arms of the 2012 BFM AML Registry protocol stratified by MRD levels after 1st induction (D28) or 2nd induction (D56). A total of 68 patients were treated in the IR (n = 36) and HR (n = 32) arms, MRD was not measured in two of these patients, and the other two patients died before D28. Data on D56 MRD were missing in one patient (BM aspiration was not performed). Of the 64 patients included in the analyses, 35 patients had KMT2A-r AML, 26 patients had AML classified into one of the other 17 subtypes (1–3 patients per subtype), and 3 patients had unclassified AML. EFS event-free survival, OS overall survival, y year, NEG. negative, POS. positive. Censoring is indicated by crosses.